References 559 & 22. Board WCoTE. WHO classification of endocrine and neuroendocrine tumours. WHO classification of tumours, 5th ed. 2022. https://tumourclassification.iarc.who.int/welcome/#. Accessed 23. Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for reporting thyroid cytopathology. J Am Soc Cytopathol. 2023. https://doi.org/10.1016/j.jasc.2023.05.005. 24. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2:1023-1029. https://doi.org/10.1001/jamaoncol.2016.0386. 25. de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, et al. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev. 2018;39:154– 191. https://doi.org/10.1210/er.2017-00133. 26. Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Annals of internal medicine. 2013;159:325-332. https://doi. org/10.7326/0003-4819-159-5-201309030-00006. 27. Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023. https://doi.org/10.1089/thy.2023.0141. 28. de Koster EJ, Vriens D, van Aken MO, Dijkhorst-Oei LT, Oyen WJG, Peeters RP, et al. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. Eur J Nucl Med Mol Imaging. 2022;49:3452-3469. https://doi.org/10.1007/s00259-022-05794-w. 29. Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH, Oyen WJ, et al. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. The Journal of clinical endocrinology and metabolism. 2014;99:3263–3274. https://doi.org/10.1210/jc.2013-3483. 30. Bossuyt PM, Reitsma JB, Linnet K, Moons KG. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem. 2012;58:1636-1643. https://doi.org/10.1373/clinchem.2012.182576. 31. Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of medical tests. Medical decision making. 2009;29:E13-21. https://doi.org/10.1177/0272989X09336144. 32. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Medical decision making. 1991;11:88-94. https://doi. org/10.1177/0272989X9101100203. 33. Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final frontier. Trials. 2012;13:137. https://doi.org/10.1186/1745-6215-13-137. 34. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet. 2000;356:1844–1847. https://doi.org/10.1016/S0140-6736(00)03246-3. 35. Ferrante di Ruffano L, Dinnes J, Sitch AJ, Hyde C, Deeks JJ. Test-treatment RCTs are susceptible to bias: a review of the methodological quality of randomized trials that evaluate diagnostic tests. BMC medical research methodology. 2017;17:35. https://doi.org/10.1186/s12874-016-0287-z. 36. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013;137:318-330. https://doi.org/10.1016/j.pharmthera.2012.11.003. 37. de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. Journal of nuclear medicine. 2006;47:770-775. 38. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [18F]-2-fluoro-2-deoxyd-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011;117:4582–4594. https://doi.org/10.1002/ cncr.26085. 39. Merten MM, Castro MR, Zhang J, Durski JM, Ryder M. Examining the Role of Preoperative Positron Emission Tomography/Computerized Tomography (PET/CT) in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules. Thyroid. 2017;27:95–102. https://doi.org/10.1089/ thy.2016.0379. 40. Piccardo A, Puntoni M, Dezzana M, Bottoni G, Foppiani L, Marugo A, et al. Indeterminate thyroid nodules. The role of (18)F-FDG PET/CT in the “era” of ultrasonography risk stratification systems and new thyroid cytology classifications. Endocrine. 2020;69:553-561. https://doi.org/10.1007/s12020-020-02239-y. 41. Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. The Journal of clinical endocrinology and metabolism. 2013;98:E914-922. https://doi.org/10.1210/jc.2012-3396. 42. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American journal of clinical pathology. 2003;120:71-77. https://doi.org/10.1309/ND8D-9LAJ-TRCT-G6QD.
RkJQdWJsaXNoZXIy MTk4NDMw